JP Morgan Upgrades ACADIA Pharmaceuticals to Overweight, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero has upgraded ACADIA Pharmaceuticals from Neutral to Overweight and raised the price target from $29 to $32.

October 10, 2023 | 9:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals has been upgraded from Neutral to Overweight by JP Morgan, with a raised price target from $29 to $32.
The upgrade from JP Morgan is a positive signal for ACADIA Pharmaceuticals. It indicates that the analyst believes the company's stock will outperform the market or its sector in the short term. The raised price target also suggests that the analyst sees potential for the stock's price to increase. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100